29 Apr Wisconsin State Journal: Stratatech hopes $28 million expansion propels growth in skin-tissue business
Stratatech, a Madison company with skin tissue to treat people with severe burns, is showing off its expanded quarters in University Research Park as it moves a step closer to seeking the government’s nod to sell its lead product, StrataGraft.
A $28 million addition onto Stratatech’s building at 535 Science Drive nearly triples the company’s space, from 13,000 square feet to 35,000 square feet, and the employee count is now 80, up from 65 last October.
The extra space will give the company enough capacity to manufacture StrataGraft for continuing clinical trials and eventually, for commercial use, if the U.S. Food and Drug Administration approves it.
“We’re very excited about this treatment,” said Steve Romano, executive vice president and chief scientific officer at Mallinckrodt Pharmaceuticals, Stratatech’s parent company.
Read the full Wisconsin State Journal article here.